The foundation:

Mercè Boada opens the new academic year of the UAB Master's Degree in Neurosciences with a conference on Alzheimer's research


Dr. Mercè Boada, medical director at Fundació ACE, opened on Friday, October 5th, the new academic year of the Master’s Degree of Neurosciences at the Universitat Autònoma de Barcelona (UAB). In the inaugural lecture of the 2018-19 academic year, Dr. Boada explained to an audience of more than a hundred people, the evolution of the research on Alzheimer's, which beyond being a health problem, has currently become a social challenge with a high cost over people, families and society.

Boada insisted on the importance of scientific research in biomarkers and the commitment to early detection as key elements in order to tackle the disease, always giving preference to the welfare of the patients and their closest environment throughout the process.

In this sense, Fundació ACE is currently participating in several international research studies on biomarkers such as FACEHBI or NORFACE, as well as in projects such as MOPEAD to promote the active participation of the patient in the early detection of the disease. In addition, the Foundation has carried out nearly 3000 open days since 2008 so that people over 55 years old can have free tests to check their memory, language and other cognitive functions.

The purpose of the Neurosciences master's degree is to offer an integral education in the field of neurosciences covering basic areas such as neuroanatomy, neurobiology, neurochemistry, neuropharmacology and neurophysiology. In addition, the master’s degree also delves into the field of neurodegenerative diseases, nerve regeneration, cognition and behavior.


Opening of the UAB Neurosciences Master 1


Opening of the UAB Neurosciences Master 2      









Opening of the UAB Neurosciences Master 3



You might also like

Dr. Mercè Boada participates in the 1st Alzheimer's Biomarkers Conference

Dr. Mercè Boada participated in the first Alzheimer's Biomarkers conference organized by Roche and targeted to neurologists, analysts and other health professionals involved in Alzheimer's disease